GRACE-DE: Prospective multicenter real-world gastric cancer patients starting AZ-developed and approved drugs in Germany (umbrella study) - GRACE-DE

Study identifier:D133HR00069

ClinicalTrials.gov identifier:NCT07882212

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Prospective, observational, multicenter, and multicohort study of patients with gastric cancer initiating AstraZeneca-developed and approved drugs in Germany GastRic CAnCEr Real-World Evidence Germany (umbrella study)

Medical condition

gastric cancer

Phase

-

Healthy volunteers

no

Study drug

-

Sex

All

Estimated Enrollment

300

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 29 Oct 2026
Estimated Primary Completion Date: 31 Oct 2031
Estimated Study Completion Date: 31 Oct 2031

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2026 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria